Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 182 million in the U.S. (IQVIA MAT November 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1396.05 as compared to the previous close of Rs. 1382.55. The total number of shares traded during the day was 30338 in over 2614 trades.

The stock hit an intraday high of Rs. 1400.00 and intraday low of 1378.95. The net turnover during the day was Rs. 42197568.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 BromfenacOphthalmicSolutions USFDA Approval 180DayExclusivity Eligible